- Innovative treatment and diagnostic methods
We offers you solutions for accurate, reproducible and qualitatively outstanding aids for patient support and patient immobilisation.
We leverage our broad base of innovative products and services to offer the most effective, state-of-the-art radiotherapy positioning solutions. Discover how we are advancing patient care in a variety of ways by exploring the information below.
We specialises in niche products in the field of innovative diagnostics. Our focus is on new methods relating to current and future diagnosis modalities.
We are driven to provide care that cures and comforts, research that informs the world, and education that enlightens and enables future generations. We proudly stand on our rich history and use it as a platform from which to embrace discovery and change.
Through our products and by bringing planning modalities such as computer tomography (CT) and positron emission tomography (PET) closer together, we can give you access to new alternatives for optimizing cancer treatment.
We are committed to making each decision, whether related to patient care, research, education or administration, based on standards that are thoughtful, informed, honest, transparent when appropriate and always respectful of privacy.
The Innovative Medicines Initiative (IMI) is a European initiative to improve the competitive situation of the European Union in the field of pharmaceutical research. The IMI is a joint initiative (public-private partnership) of the DG Research of the European Commission, representing the European Communities, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI is laid out as a Joint Technology Initiative within the Seventh Framework Programme. Michel Goldman was the first executive director, from September 2009 until December 2014.
The Innovative Medicines Initiative is aimed towards removing research bottlenecks in the current drug development process. The IMI Joint Technology Initiative (IMI JTI), to be implemented by the IMI Joint Undertaking is meant to address these research bottlenecks. Its €2bn budget makes it the largest biomedical public-private partnership in the world.